RISK OF MULTIPLE RECURRING RETINAL DETACHMENT AFTER PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT REPAIR
Overview
Affiliations
Purpose: To evaluate functional and anatomical outcomes of patients with retinal redetachments (re-RD) after surgery for primary rhegmatogenous retinal detachment.
Methods: Medical records of eyes with re-RD after rhegmatogenous retinal detachment surgery between 1999 and 2014 at the Department of Ophthalmology, University of Cologne, Germany, were retrospectively evaluated. Data included preoperative and postoperative clinical findings, best-corrected visual acuity, presence and grade of proliferative vitreoretinopathy, surgical procedures, and complication rates.
Results: Three hundred and twenty-eight eyes of 2,457 developed a re-RD (13.3%). Of these 328 eyes, 242 eyes (73.8%) had only one re-RD, whereas 86 eyes (26.2%) had 2 or more re-RDs. Visible presence of proliferative vitreoretinopathy during first redetachment surgery increased risk of re-RD with relative risk ratio of 1.46 (P = 0.05). Best-corrected visual acuity deteriorated with every additional re-RD (P < 0.001). Two hundred and thirty-seven eyes received oil endotamponde at least once. In 91 cases, oil endotamponade was left for long-term until last follow-up.
Conclusion: Multiple re-RD (≥2 re-RDs) is an infrequent complication after rhegmatogenous retinal detachment surgery. After a first re-RD occurred, risk for multiple re-RD doubles compared with the risk of a first redetachment. Mean functional outcome is unfavorable, whereas predictability remains nevertheless poor because of the wide range of interindividual postoperative best-corrected visual acuity.
Ramachandran Nandhakumar O, Khare G, Kohli P Indian J Ophthalmol. 2024; 72(8):1224-1226.
PMID: 39078972 PMC: 11451799. DOI: 10.4103/IJO.IJO_1879_23.
Hyalocytes-guardians of the vitreoretinal interface.
Lange C, Boneva S, Wieghofer P, Sebag J Graefes Arch Clin Exp Ophthalmol. 2024; 262(9):2765-2784.
PMID: 38568222 PMC: 11377362. DOI: 10.1007/s00417-024-06448-3.
Hyalocytes in proliferative vitreo-retinal diseases.
Jones C, Gui W, Schumann R, Boneva S, Lange C, van Overdam K Expert Rev Ophthalmol. 2022; 17(4):263-280.
PMID: 36466118 PMC: 9718005. DOI: 10.1080/17469899.2022.2100764.
Bai J, Zheng W, Zhu X, Peng X BMC Ophthalmol. 2022; 22(1):439.
PMID: 36384489 PMC: 9670523. DOI: 10.1186/s12886-022-02665-8.
Hsu C, Yang C J Clin Med. 2022; 11(16).
PMID: 36013094 PMC: 9410417. DOI: 10.3390/jcm11164856.